Alzheimer's disease (AD) is one of the most widely known of the organic mental disorders described as dementias. It is apparent, in both the USA and the UK, that AD imposes a large economic burden in terms of both formal and informal costs. In the UK, one estimate is that annual costs are about £, million at \ prices and another, even higher, at £, million. There is an extremely heavy burden on informal caregivers, and on agencies providing social services and residential accommodation.
Introduction
The group of organic mental disorders described as dementias are chronic and progressive in nature and, if untreated, are usually irreversible and terminal. There are several types of dementia, but this review focuses on Alzheimer's disease (AD). This illness can occur at any age but is usually associated, in the public mind, with older persons. It is certainly an age-related condition, with prevalence increasing with age (Jorm  ; Kay and Bergman ).
The causes of AD are still unclear, although a variety of hypotheses have been put forward, including virus diseases, aluminium in the central nervous system, and defects in the immune system. A number * MEDTAP International, London of significant risk factors associated with incidence have also been identified (Brayne  ; van Duijn et al. ) , including a family history of dementia, Parkinson's disease, head trauma and hypothyroidism. The management of AD has also been highly problematic to date, with no effective therapy or clinical intervention available. Care has been restricted to providing support for patients and caregivers. There are no treatments currently available in the UK that will retard or reverse the progression of the disease.
Economic perspectives
There has been a large amount of work published recently in this area (see Tables  and ) . Much of the earlier work was summarised by Keen () in an OHE pamphlet which concluded with a section entitled Prospects for the s. This looked forward (from ) to the future course of events. The general conclusion reflected a consensus view of the prospects for AD.
The key factor in the UK, following on from the s, was the introduction of the government policy of care in the community. This approach placed a stress on (i) reducing the role of long-stay psychiatric and geriatric hospitals, with reductions in available bed numbers, and (ii) a shift towards either residential care, with the increased provision coming from the private sector, or domicilary care. A particular stress was placed on the objective of keeping people at home as long as possible. Thus, if there are cost differences between caring for patients at home and those in institutions, these will have great economic impact.
These priorities for the mode and duration of care have been retained in the s, within new and changing administrative structures. There is an ongoing debate about the most desirable sources of funding and the mechanisms of administration. Any reforms of financing care are liable to be geared to maintaining the incentives for people to remain in their own homes receiving domiciliary care. But this ability to remain at home is affected by the level of dependency of each individual person. As the population of older persons rises, the numbers suffering from AD will rise, posing a problem for the health care system in terms of the provision and financing of care. It is in this context that pharmaceutical innovation must be seen. It is an area of growing demand and resource usage, which is linked to changes in the levels of severity and dependence. The most effective treatment may well be that which is best at retarding a patient's progression through T  . A U S levels of dependency, or even reversing that process. The consequence of this will be to retard progression through levels of resource usage and expense.
Epidemiology and prevalence
The epidemiology and prevalence of AD is an important element in the public health implications of an ageing population (Brayne ). Evaluation, however, is made more complex because of the difficulty of separating a diagnosis of AD from other dementias (Hofman et al. ) . Once established, prevalence rises with age, with one study estimating an additional incidence of . per  persons per year of age, in a sample aged over  years (Copeland et al. ) . The cost implications of the prevalence of dementias were examined by Smith et al. () . One significant point in their report is that dementia accounts for  per cent of the bed occupancy in psychiatric hospitals. The main pressure group acting in this area in the UK is the Alzheimer's Disease Society. In  it produced ' Home Alone ', a report on the plight of persons living alone with dementia. They identified approximately , persons in the UK currently falling into this group, with the figure projected to rise to , by . This followed an earlier report (Alzheimer's Disease Society ) which laid particular stress on the inevitable increase in the prevalence of AD with an ageing population. Data from the General Household Survey (OPCS ) shows the tremendous burden on informal carers.
$ There are  million carers in the UK. $ . million are women. $ . million are men. $ . million carers shoulder the responsibility alone. $ . million carers spend at least  hours per week providing care and support. $  per cent of carers care for a relative. $ over  per cent are caring for parents or parents-in-law. $  per cent have been caring for more than five years. $  per cent of people can expect to become carers during retirement.
Resource use and the cost of illness
Table  lists some recent studies that estimate the health and social services resource use associated with the care of people with AD. This is a growing area of literature. Nevertheless, some theoretical and methodological doubts exist about the validity of the cost of illness approach (CoI) as economic analysis. The key issue is that, while CoI studies illustrate the overall cost burden, they provide no guidance as to how the burden can be reduced or redistributed.
One early paper (Colerick and George ) assessed the probabilities of AD patients being institutionalised, focusing on the characteristics of caregivers rather than the patients. This contrasts with assumptions of many other students which look to patient status, dependency and disability as the key predictors of the transition from home to institutional care. Colerick and George found a number of significant differences between those who were institutionalised and those who were not. The caregivers of those who were institutionalised were more likely to be female, younger, employed and caring for their parents. These are just some of the factors identified by Colerick and George and they emphasise that there may be underlying difficulties with any attempt at a reductionist analysis of this area.
One of the earliest studies (Max ) focused on the issue of an ageing population as leading to a greater burden of AD. The author notes that there are currently . million persons with AD in the USA, and that by  this may rise to  million. The paper then examines the economic impact of AD with respect to three key questions :
What is the cost of AD to society ? . Who bears the financial burden of AD ? . What is the future economic impact of AD likely to be ?
In answer to the first question, the standard economic basis to the answer is that : ' the cost of AD to society is the value of all goods and services that society gives up in order to prevent, diagnose, treat and otherwise contend with the disease '. That is, it is the opportunity cost. Max gives some figures for this, quoting from CoI studies which will be discussed later ( Table ) .
The second question is more interesting. In the US context, Max details a range of public programmes including Medicare, Medicaid and Social Security Disability Insurance (SSDI). They are inadequate to cover all finance needs however, and are also seen to be biased toward acute care and medical needs. For many AD patients, he argues, the primary need is for social services. The gaps in coverage, even after support from private insurance, ensure that AD often becomes a major drain on the pockets of the families of patients. The importance of this US-oriented question may become more relevant in countries such as the UK, with the continuing development of a ' mixed economy ' of care. This involves private individuals, health authorities and social services, all acting as purchasers of care services provided by a variety of agencies. The third question, the likely future impact of AD, Max sees as particularly significant for long-term care. This is perhaps inevitable given the stress he places on the ageing of the population and the agerelated prevalence of AD. These factors pose questions for the current organisation and financing of the US system of health care.
One of the papers reviewed by Max is Ernst and Hay (), itself a reworking of  estimates of the per case and national costs of AD. They use US studies, supported by extra data from Sweden and Israel, to calculate prevalence and incidence and then to construct estimates of annual costs covering both direct and indirect costs. These include caregiver costs and loss of lifetime earnings. At \ price levels, this estimate was $, to $, per patient per year, giving annual prevalence costs of $. billion. One of the important points drawn by the authors is that, in relation to home-dwelling patients, the bulk of costs (approximately $,) falls on caregivers.
However, while these observations are of interest, some of the assumptions used in the evaluation have to be questioned. Two in particular stand out : (i) that the stream of costs starts at diagnosis, at which point the patient becomes completely disabled ; (ii) that the patient's annual costs are constant from diagnosis to death. After diagnosis, however, patients with AD do not immediately become disabled. Instead, their cognitive ability declines at a rate that varies from patient to patient (Brayne  ; Copeland et al. ) . This error in the first point leads to the second. As severity of dementia increases, changes can be observed in the type of care provided and hence in the costs of this care (Kavanagh et al.  ; Schneider et al. ) .
Consequently, annual costs of care will almost certainly vary between diagnosis and death.
A more general paper (Harrow et al. ) examined an issue relevant to Ernst and Hay's conclusions, relating to the costs of providing care in a community setting. They followed a sample of disabled elders over a seven-year period, collecting data on the receipt of formal and informal care and services. The distribution of costs was interesting, as it emerged that the ' high cost ' elders, defined as those with costs falling in the top quartile of the distribution, accounted for over half of total costs in each time period, although by definition they represented only  per cent of the sample. The pattern of change in costs showed that those elders who were initially the most minimally disabled experienced the highest increases in costs, as their level of functioning declined. Further, for all elders whose level of disability increased, the costs of community care also rose. As later papers in this review will describe, AD is a degenerative illness and so care demands will vary widely over time.
Max followed up his earlier paper and reviewed a further series of studies (Max ) . The issue of drug therapy was examined, identifying some of the areas where the response to therapy could result in lowered costs. If drugs can be of any therapeutic or palliative effect, then possible benefits would include :
$ a delay in the institutionalisation of the patient ; $ a reduction in the number of hours of informal caregiving required in the short term ; $ an improvement in the quality of life for patients and caregivers.
These are, however, hypothetical benefits, open to question by empirical studies. In particular, the assumption that a delay in institutionalisation of patients will reduce costs of care may not stand up to a rigorous examination of the formal and informal costs.
There are now several studies that have examined the costs issue in the UK context. They have examined different but related patient groups, and vary in their specific focus. Schneider et al. () examined elderly persons with advanced cognitive impairment. They identified where people in this group were living, what resources they used and what costs the provision of those resources imposed on the funding agency. For persons with dementia, the analysis, based principally on OPCS data, showed that residence was primarily in private households (. per cent). Actual service receipt was difficult to measure in private households, but evidence showed higher use by those living with others compared with those living alone. The total cost burden, at \ prices, was £, million, including client and Social Security payments. Reinforcing the US evidence, this study revealed the extremely heavy burden on clients and families, who are estimated to bear up to  per cent of the costs. A subsequent paper from the same research programme (Kavanagh et al. ) explored the resource consequences of shifts between different models of care in different settings. In this analysis, cost functions were estimated to identify the factors determining variations in costs. High levels of dependency, as implied by advanced levels of cognitive impairment, imposed extra care costs of around  per cent, assuming other patient and location characteristics were unchanged. The authors demonstrated that substantial changes in resource use and costs of care, would occur if purchasers and providers made changes in the balance of care. This could involve a shift between residential and domiciliary care, or a move towards intensive support services for informal carers and clients living at home.
As Kavanagh et al. () illustrate, a major influence on costs is the location in which a person with dementia is cared for. The general conclusion is that the highest costs are associated with institutionalisation, represented by the various forms of residential care. A review commissioned by the Department of Health (DoH , quoted in Warburton ) examined the factors involved in movement from home to institutionalisation. It identified a division between demand side and supply side factors. The demand side factors reflect the characteristics of older population groups, the link between age and admissions, and also a link with health problems that have generated a prior admission to hospital. Many older people move directly from hospital to residential care. Dementia was shown to be a major influence in movements into residential homes, partly reflecting the stress on carers supporting people with dementia at home. Schneider et al. () estimate that over a third of elderly persons with severe cognitive impairment are cared for in residential or nursing homes. This group was also disproportionately located in Local Authority homes rather than the residential care homes and nursing homes of the independent sector (ADSS , quoted in Warburton ).
When the supply side is examined, other factors are seen to be important. If support and assistance is provided to clients and their carers, this can have the effect of enabling them to remain at home, although at a cost. It has also been observed that the provision of such domiciliary care is biased towards those living alone (Neill et time focused on AD and assessing costs in England alone. They estimated direct and indirect costs, separating costs into the main areas of provision : hospital and residential care, general practice, day care, home care and informal care. Prevalence and resource-use data were collected from a variety of sources, and produced an estimated annual cost of £, million at \ prices. Of that figure, a high proportion was devoted to institutional care rather than community care. Over  per cent was accounted for by residential and nursing homes, and  per cent by hospital-based care. By service provider, the breakdown of the formal costs of care is shown in Table  . It was noted that informal care, provided by relatives and friends, was almost certainly under-estimated. The figure only quantifies the burden covered by payments made by the Department of Social Security as measured by the payment of an attendance allowance. Despite this, the figure does provide a starting point in calculating costs in this area. The extent of its under-reporting may be apparent in the contrast with the estimates by Schneider et al. () noted above. They deal with a slightly wider population group but their estimate of the cost burden was over four times higher at £, million (- prices). Smith et al. () , reviewed in the discussion of prevalence, also provide estimates of costs. Their methods were very similar to those of Gray and Fen, but indirect costs were not included. They were, however, based on  prices which, to ensure consistency with the prevalence data that they were using, were inflated to \ prices. Given this, the actual costs reflect the costs of standard responses and packages of care that existed in . By - it was not just prices that had changed, so also had approaches to care provision. Therefore, merely to inflate costs from the earlier date does not give an accurate view of actual costs of care at the later date, as the package of resources provided may well have changed. Indeed, given the range of policy innovations over the period between  and , the changes may have been very significant.
A report by the Alzheimer's Disease Society () provides some foundation for these CoI estimates in its identification of particular needs associated with dealing with AD. Regarding the needs of carers, for example, the factors listed include : information, advice and counselling ; regular help with household and personal tasks ; regular breaks (from the duties of caring) ; regular financial support (to cover extra expenses and reduced employment opportunities). It is clear that there are resource and financial consequences to all of these factors. The situation at that time was one of transition, with the introduction of new community care policies, accompanied by the transfer of monies from the Department of Social Security to local authorities. At the time, April , local authority associations estimated that there would be a shortfall of £ million. This emphasises the potential scale of the problem in funding and providing care. It is the type of problem that can successfully be identified by CoI studies : the next stage is to identify how to cope with that funding gap.
There is the additional question of how much of the burden of illness in the patient group is accounted for by their illnesses and how much is accounted for by their age. Some of the issues around this question were tackled by Philp et al. () who, in the context of evaluating community care, compared community-based samples of demented and non-demented elderly people. One of their conclusions was that, although the financial impact of care was low, carers of persons with dementia had significant extra household expenses, although these were not defined. The extra burden of dementia was also shown in the mean number of days' contact per week per carer : seven days for those caring for persons with dementia as against four days for carers of nondemented elderly persons. The proportion having to provide or arrange care was . per cent in the dementia group compared with only . per cent in the comparator group. This analysis illustrates how caregivers bear a significant part of the costs generated by dementia.
A fundamental problem with the traditional approach to CoI evaluation is that it is based on an aggregate of costs that is not linked to outcomes or effectiveness of treatments. In considering various alternatives for the balance of care provision, Kavanagh et al. () make the point that maximising client outcomes may only be achieved at a higher cost. Establishing whether the outcomes justify this higher cost requires a different form of evaluation. It also requires a societal judgement that the cost of care for an illness is justified by the health outcomes achieved.
Almost all the evidence from clinical studies suggests that decline is progressive and leads to greater dependency of the patient with dementia. This may lead to institutionalisation and definitely leads to greater strain on caregivers. Evidence of this comes from an American clinical trial of drug therapies (Clipp and Moore ). They measured cognitive functioning using the Alzheimer's Disease Assessment Scale (ADAS) and caregiver time (paid and unpaid) using the Caregiver Activities Time Survey (CATS). Their results showed an increase in unpaid caregiver time at the baseline associated with levels of cognitive impairment. In the patient groups receiving active drug therapy (velnacrine maleate), an improvement was observed in their cognitive functioning relative to the placebo group. This was associated with a trend towards a decrease in unpaid caregiver time. The main effect claimed was that caregivers in the high dose patient group experienced a partial release from time involvements, by an average of . hours per day. Given the high level of time given by caregivers of people with dementia shown by Philp et al. () , such reductions in time involvements could have a great impact on informal care costs.
All clinical development of velnacrine ceased in , however, following concerns about potential liver toxicity and gastric sideeffects. The product was a metabolite of a more widely tested compound, tacrine. The largest study of tacrine, a multi-centre trial, was reported in  (Knapp et al. ) . Patients were allocated to placebo or to three separate dosage levels of tacrine. At the end of the -week trial,  per cent of patients remained in the study. Some improvements were shown : for the highest dose group, the Clinician Interview Based Impression Score showed a  per cent improvement in the tacrine treated patients, against  per cent for the placebo group. Side-effects were the main reason for not completing the study and, as with velnacrine, liver toxicity was a problem, occurring in  per cent of patients. The results of this trial were summed up as showing ' that a minority of patients may show a meaningful improvement in their mental state on the highest dose tacrine and there might be a slight slowing of the rate of deterioration of the brain in such patients' (Leonard ) . Despite these possibilities, the UK Committee on Safety of Medicines turned down tacrine's licensing application in . It was unconvinced that the drug's efficacy was sufficient to override the side-effects.
In association with clinical evidence, the assessment of the technical efficiency of available therapies and interventions, is shifting towards the use of economic evaluation techniques. This process is not mandatory for new medicines in the UK, although the Department of Health has published guidelines as to how such evidence should be produced and presented. Some recent examples of economic evaluations are shown in Table  .
One of the first attempts to evaluate treatment for AD patients was undertaken by Lubeck et al. () . They analysed the benefits of tacrine treatment using figures from Knapp et al. () . The key clinical measure for this study was the Mini Mental State Examination (MMSE). Over a -week treatment period, improvements were observed in the tacrine treatment group, whilst the placebo group continued to deteriorate. Following completion of treatment, the tacrine group resumed their decline, but still showed an improvement relative to the placebo group at the expected point of death. The underlying assumption of the economic analysis was that, by deferring the process of decline, treatment would also defer the costs of care, particularly by delaying the requirement for intensive community based care, and by delaying institutionalisation. Therefore, it was argued, a process of prolonging independence will have substantial economic advantages, as care remains on lower cost settings. In other contexts, this assumption has been challenged, and attention has been drawn to the variety of factors determining the costs of care (see, for example, von Abendorff et al. ). But Lubeck and colleagues, maintaining the assumptions of the model, predicted that . months of community and institutional care (over a mean life expectancy of . years) could be avoided for each person treated with tacrine, as assessed by their performance on the MMSE. For those who were able to tolerate high dose treatment, the predicted saving was higher at . months of care. These figures correspond to savings of $, to $, per person per annum, leading Lubeck to conclude that tacrine offers great potential for economic benefits.
An important issue in judging this evaluation is the division between the formal costs of care being covered by health and social services authorities, and the informal care costs borne by the carers, usually partners or children, of AD patients living at home. As yet there is no definitive estimate of informal care costs, but undoubtedly they are very high. It may be that a shift to institutional care would actually reduce overall care costs, while simultaneously making them more ' visible ' by shifting the balance away from informal, often unseen, care costs, towards those borne by formal service providers. This issue is critical, given the key assumptions in the Lubeck et al. model. A less sanguine view of tacrine's potential costs and benefits is offered by Knopman () . This paper reviewed the available clinical evidence, including Knapp et al. () , the main source for Lubeck's evaluation. In a simple evaluation, costs were calculated for the care and monitoring associated with tacrine treatment and for nursing home care. This is significant, as it is assumed that the main economic benefit of tacrine is the potential to delay entry into nursing home care. Using the figures of Knapp et al. () , Knopman estimated that only  per cent of patients would comply with the full six month course and only  per cent would derive significant benefits. This leads to the conclusion that tacrine would have to delay nursing home entry by over nine months before an economic case could be made for its use. That figure is beyond the suggestions made by Lubeck, and also does not account for Knopman's estimates that, in the USA, only  per cent of AD patients are serious candidates for tacrine therapy for reasons of co-morbidity, personal situation and clinical status. This analysis still accepts the assumption that the key factor in estimating costs of care for AD patients is the point at which the location of care shifts from home to institution. As stated earlier, this may be hiding the true level of informal care costs. However, it does illustrate a methodological point for economic evaluations : by using models, key factors such as the location of care can be tested and re-evaluated to gradually obtain more accurate results.
The two papers discussed above do not agree in their conclusions on cost-effectiveness, but they do agree that the formal costs of institutional care should be the main economic cost driver within the evaluation of treatment for AD. Max () partly supports this in noting the wide variety of evidence that supports the dominance of nursing-home charges within the overall costs of formal care. However, as Max points out, delaying institutionalisation may not actually reduce total costs. Where patients are able to remain in their home environment for longer, the cost to families may be prolonged and increased. In fact, where patients remain at home, informal care accounted for  per cent of costs, while the equivalent figure for patients in nursing homes is only  per cent. Max concludes that ' any drug therapy that delays institutionalisation is likely to reduce the [health services] direct cost and increase the indirect cost of formal care, ( : ). In fact not only is budget shifting inevitable, depending on the relative levels of direct and indirect costs and formal versus informal care, it may be that the cost of illness is actually increased.
There is clearly great scope for research in this area and particularly for more substantial economic evaluations of approaches to the treatment and management of Alzheimer's disease. However, the available literature does support some clear conclusions on AD and potential therapies.
$ The disease is widely prevalent, especially in those over  years of age, and changes in the age profile of the UK population are likely to lead to an increase in the incidence of AD. $ Morbidity associated with AD leads to very high economic costs, direct and indirect, formal and informal. $ One of the most significant drivers of direct health and social services costs is the requirement for residential care, although the associated variation in indirect and informal costs is more complex. $ Costs are often assumed to be linked to levels of functioning and dependency, but a variety of other patient and caregiver characteristics are also significant. $ No drug interventions have yet been clearly demonstrated to show a significant economic benefit, in a robust manner.
Future economic prospects for AD and the care of AD patients are far less clear. AD is an area where new drug therapies are being introduced. It differs from other areas of pharmaceutical innovation, such as the treatment of schizophrenia and depression, in that these new AD drugs are not supplanting an existing therapy. There are no existing treatments in this area and so what is being offered is an additional cost to the health service. As shown earlier, the costs of caring for people with AD are high and are likely to rise with an ageing population. Innovative treatments may be shown to bring better health outcomes but that may not be sufficient to justify their use. There will have to be a decision at a societal level, that the health gains justify the extra of resources.
